About 14 results found for searched term "TLR7-agonist-1" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6246 | TLR7-agonist-1 | TLR |
| TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM. | ||
| M10918 | TLR7/8 agonist 1 dihydrochloride | TLR |
| TLR7/8 agonist 1 dihydrochloride is a dual agonist of toll-like receptor TLR7/TLR8. | ||
| M28075 | TLR7/8 agonist 1 | TLR |
| TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. | ||
| M41562 | TLR7 agonist 13 | Nucleoside Antimetabolite/Analog |
| TLR7 agonist 13 is a guanosine analog. | ||
| M2728 | Vesatolimod (GS-9620) | TLR |
| GS9620 | ||
| Vesatolimod (GS-9620) is an effective, selective, oral toll-like receptor 7 (TLR7) agonist with an EC50 value of 291 nM. | ||
| M10704 | SM-276001 | TLR |
| SM-276001 is a potent and selective TLR7 agonist that induces an antitumor immune response. SM-276001 is an orally active interferon (IFN) inducer. | ||
| M10824 | GSK2245035 | TLR |
| GSK2245035 is a highly potent, selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential stimulation of interferon type 1 (IFN). GSK2245035 for IFNα and TNFα pEC50 9.3 and 6.5, respectively. GSK2245035 effectively inhibits allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 has the potential for asthma. | ||
| M11411 | 1V209 | TLR |
| TLR7 agonist T7 | ||
| 1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist with antitumor effects. 1V209 can be conjugated with various polysaccharides to improve their water solubility, enhance efficacy and maintain low toxicity. | ||
| M27651 | Gardiquimod | TLR |
| Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM. | ||
| M27867 | Gardiquimod diTFA | TLR |
| Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM. | ||
| M27993 | BBIQ | TLR |
| BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses. | ||
| M29469 | SM-360320 | TLR |
| CL-087 | ||
| SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity. | ||
| M30420 | 3M-011 | TLR |
| 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action. | ||
| M42063 | TLR7/8 agonist 8 | TLR |
| TLR7/8 agonist 8 is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
